merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>significant safety risks, including swelling and bleeding in the brain</answer>
<question_number>2</question_number>
<answer>might discourage patients from participating in trials for potentially better treatments</answer>
<question_number>3</question_number>
<answer>no correlation between removal of amyloid plaques and clinical response in individual subjects</answer>
<question_number>4</question_number>
<answer>raises concerns about Kisunla's safety compared to Leqembi</answer>
<question_number>5</question_number>
<answer>patients can stop Kisunla after plaques are cleared, reducing overall cost and inconvenience</answer>
<question_number>6</question_number>
<answer>some patients might avoid other trials due to focus on anti-amyloid drugs</answer>
<question_number>7</question_number>
<answer>Kisunla is given monthly, while Leqembi is given every two weeks</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels</answer>